Madrigal Pharmaceuticals, Inc. (MDGL)
120,000 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Purchased by Alkeon Capital Management LLC
Alkeon Capital Management LLC bought a new stake in Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 120,000 shares of the biopharmaceutical company's stock, valued at approximately $55,039,000. Alkeon Capital Management LLC owned
Madrigal Q4 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Down
MDGL swings to a wider Q4 loss as expenses surge, but Rezdiffra sales top estimates and fuel revenue growth. The stock slides 11% in response to the mixed nature of the results.
Madrigal Pharmaceuticals, Inc. (MDGL) Q4 2025 Earnings Call Transcript
Madrigal Pharmaceuticals, Inc. (MDGL) Q4 2025 Earnings Call Transcript
Madrigal (MDGL) Reports Q4 Loss, Beats Revenue Estimates
Madrigal (MDGL) came out with a quarterly loss of $2.57 per share versus the Zacks Consensus Estimate of $0.04. This compares to a loss of $2.71 per share a year ago.
Madrigal Pharmaceuticals: What To Expect With Q4 Earnings Coming Thursday
Madrigal Pharmaceuticals is reiterated as a Strong Buy ahead of Q4 earnings, with a 12-month price target of $665, implying 43% upside. Rezdiffra's rapid commercialization and first-mover advantage in the MASH market underpin robust sales growth, with Q3 net sales at $287.3M and >29,500 active patients. Geographic expansion in Europe, pipeline catalysts (F4 trial), and under-diagnosis of MASH provide a long growth runway and potential for upside surprises.
MDGL Strengthens MASH Franchise With New Genetic Approaches
Madrigal inks $4.4B siRNA licensing deal with Ribo in $60M upfront pact, adding preclinical candidates, expanding MASH pipeline and eyeing FDA filings in 2026.
Madrigal (MDGL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Madrigal (MDGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
MDGL Secures Exclusive Global Right for MASH Treatment From PFE
Madrigal Pharmaceuticals obtains global rights to Pfizer's ervogastat. It intends to pair it with Rezdiffra to advance combination therapies for MASH.
Madrigal (MDGL) Up 21.9% Since Last Earnings Report: Can It Continue?
Madrigal (MDGL) reported earnings 30 days ago. What's next for the stock?
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Jefferies London Healthcare Conference 2025 Transcript
Madrigal Pharmaceuticals, Inc. ( MDGL ) Jefferies London Healthcare Conference 2025 November 20, 2025 3:30 AM EST Company Participants William Sibold - CEO, President & Director Mardi Dier - Executive VP & CFO David Soergel - Executive VP & Chief Medical Officer Conference Call Participants Akash Tewari - Jefferies LLC, Research Division Presentation Akash Tewari Jefferies LLC, Research Division Good morning, everyone. We've made it to our last day of our London Healthcare Conference.
Madrigal Q3 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Up
MDGL's wider Q3 loss fails to deter investors, as soaring Rezdiffra sales drive revenues past estimates and lift the stock.
